Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a leading Chinese pharmaceutical company, has announced a strategic partnership agreement with domestic firm SPH KDL Health. The collaboration aims to enhance the marketing efforts of Wuzhong Pharmaceutical’s medical aesthetics subsidiary’s polylactic acid facial filler, AestheFill. The partnership encompasses commercial distribution, expansion of customer resources, strengthening of brand collaboration, and integration of market channels. Financial details of the agreement have not been disclosed.
AestheFill, a medical aesthetics regeneration injection developed by South Korean firm REGEN Biotech Inc., is composed of PDLLA microspheres and sodium carboxymethyl cellulose. The product received its initial approval in South Korea in 2014 and recently gained approval in China, marking a significant step forward in its commercialization within the Chinese market.
This strategic partnership highlights the growing focus on medical aesthetics in China and the potential for collaboration between domestic companies to expand market reach and brand influence in this rapidly growing sector.- Flcube.com
